Peter Houghton, PhD

  • Rank: Professor
  • Department: Molecular Medicine
  • Institute: Director, Greehey Children's Cancer Research Institute
  • Office: 2.110.12
  • Location: Greehey CCCRI
  • Tel: 1.210.562.9056

 

Our studies are aimed at understanding mechanisms of cancer initiation in children and using this information to develop more effective and less toxic treatments that will increase the cure rate and improve quality of life for cancer survivors.

 

Research Project A

Signaling pathways in childhood sarcoma

Our earlier studies have identified insulin-like growth factor (IGF) signaling as maintaining proliferation of sarcoma cells, and to be involved in angiogenesis by regulating vascular endothelial cell response to VEGF. The current studies, supported through a Program Project Grant from NCI, are aimed at identifying mechanisms of resistance to therapeutics that target the IGF-axis. These studies integrate IGF, STAT3 and NFκB signaling pathways in childhood sarcoma models both in vitro and in vivo.

Find out more

Research Project B:

The Pediatric Preclinical Consortium (PPTC)

The PPTC builds upon 10 years testing of novel agents against panels of cell lines in vitro and tumor xenografts models in mice that represent childhood solid tumors, brain tumors and acute lymphoblastic leukemias. Over 80 drugs or drug combinations have been tested in 83 models of childhood cancer (kidney cancers, sarcomas, neuroblastoma, brain cancers and acute lymphoblastic leukemia). These studies have identified novel drugs and drug combinations that are now in clinical trial.

Find out more

Research Project C:

Low-Grade Glioma – Brain tumors

Low-Grade gliomas are ‘driven’ by an activated mutant protein ‘BRAF’. We identified a drug that inhibits a kinase (MEK) downstream in the signaling cascade and causes death of these cancer cells. The drug, selumetinib, has recently completed phase I testing through the Pediatric Brain Tumor Consortium (PBTC), and shows promising activity. This project builds upon our initial work to develop effective therapies that prevent or retard emergence of drug resistant cells, and to explore the therapeutic value of combining selumetinib (or alternate MEK inhibitors) with radiation therapy.

Find out more

 

 

The overall goal of this Program Project Grant is to acquire a comprehensive understanding of the interrelationship between NF-κB, STAT3, and IGF signaling pathways in childhood sarcomas (rhabdomyosarcoma, Ewing sarcoma, osteosarcoma) that can be leveraged to develop novel more effective therapies for treating patients. These goals will be achieved through the combined expertise of the principal investigators in childhood sarcoma biology and pediatric cancer drug development, the incorporation of unique small and large animal models of childhood sarcoma, and the broad interactions between Projects 1-3. The basic premise for the work proposed is that each of the three pathways to be studied is important for sarcoma cell proliferation and survival, but that by virtue of the dynamic nature of cellular signaling, these pathways are interactive and combinatorial inhibition may be essential to achieve maximum therapeutic efficacy. A schematic showing Project interactions and specific pathways to be studied in each Project are shown:

 

 

P53 suppresses ribonucleotide reductase via inhibiting mTORC1. He Z, Hu X, Liu W, Dorrance A, Garzon R, Houghton PJ, Shen C. Oncotarget. 2017 Apr 26. doi: 10.18632/oncotarget.17440. [Epub ahead of print] PMID:28507282

Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Zhou X, Liu W, Hu X, Dorrance A, Garzon R, Houghton PJ, Shen C. Sci Rep. 2017 May 8;7(1):1535. doi: 10.1038/s41598-017-01729-w. PMID:28484242

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. Jones L, Richmond J, Evans K, Carol H, Jing D, Kurmasheva RT, Billups CA, Houghton PJ, Smith MA, Lock RB. Clin Cancer Res. 2017 Jan 24. doi: 10.1158/1078-0432.CCR-16-2392. [Epub ahead of print] PMID:28119366

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA. Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26304. Epub 2016 Oct 27. PMID:27786412

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26263. Epub 2016 Sep 21. PMID:27650817

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Kurmasheva RT, Sammons M, Favours E, Wu J, Kurmashev D, Cosmopoulos K, Keilhack H, Klaus CR, Houghton PJ, Smith MA. Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26218. Epub 2016 Aug 24. PMID:27555605

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ. Cancer Res. 2016 Oct 1;76(19):5798-5809. Epub 2016 Aug 5. PMID:27496711

Hypoxic Proliferation of Osteosarcoma Cells Depends on Arginase II. Setty BA, Jin Y, Houghton PJ, Yeager ND, Gross TG, Nelin LD. Cell Physiol Biochem. 2016;39(2):802-13. doi: 10.1159/000447790. Epub 2016 Aug 1. PMID:27475813

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, Billups CA, Erickson SW, Guo Y, Houghton PJ, Smith MA, Carol H, Roberts AW, Huang DC, Lock RB. Blood. 2016 Sep 8;128(10):1382-95. doi: 10.1182/blood-2016-03-707414. Epub 2016 Jun 24. PMID:27343252

Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA, Carol H, Heatley S, Sutton R, Marshall GM, White D, Pimanda J, Houghton PJ, Smith MA, Lock RB. Cancer Res. 2016 Aug 1;76(15):4579-91. doi: 10.1158/0008-5472.CAN-16-0523. Epub 2016 Jun 14. PMID:27302164

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Pediatr Blood Cancer. 2016 Oct;63(10):1744-52. doi: 10.1002/pbc.26064. Epub 2016 May 30. PMID:27238606

Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL. Churchman ML, Evans K, Richmond J, Robbins A, Jones L, Shapiro IM, Pachter JA, Weaver DT, Houghton PJ, Smith MA, Lock RB, Mullighan CG. JCI Insight. 2016;1(4). pii: e86082. Epub 2016 Apr 7. PMID:27123491

Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia. Dolai S, Sia KC, Robbins AK, Zhong L, Heatley SL, Vincent TL, Hochgräfe F, Sutton R, Kurmasheva RT, Revesz T, White DL, Houghton PJ, Smith MA, Teachey DT, Daly RJ, Raftery MJ, Lock RB. Cancer Res. 2016 Mar 9. pii: canres.2786.2015. [Epub ahead of print] PMID:26960974

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Bid HK, Phelps DA, Xaio L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ. Mol Cancer Ther. 2016 May;15(5):1018-28. doi: 10.1158/1535-7163. MCT-15-0567. Epub 2016 Feb 23. PMID:26908627

The role of FLI-1-EWS, a fusion gene reciprocal to EWS-FLI-1, in Ewing sarcoma. Elzi DJ, Song M, Houghton PJ, Chen Y, Shiio Y. Genes Cancer. 2015 Nov;6(11-12):452-61. PMID:26807198

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Pediatr Blood Cancer. 2016 Mar;63(3):443-50. doi: 10.1002/pbc.25826. Epub 2015 Nov 24. PMID:26797892

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.Pediatr Blood Cancer. 2016 Feb;63(2):276-86. doi: 10.1002/pbc.25727. Epub 2015 Sep 23. PMID:26398108

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ. Front Oncol. 2015 Aug 26;5:193. doi: 10.3389/fonc.2015.00193. eCollection 2015. Review. PMID:26380223

Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Forest A, Amatulli M, Ludwig DL, Damoci CB, Wang Y, Burns CA, Donoho GP, Zanella N, Fiebig HH, Prewett MC, Surguladze D, DeLigio JT, Houghton PJ, Smith MA, Novosiadly R. Mol Cancer Res. 2015 Dec;13(12):1615-26. doi: 10.1158/1541-7786.MCR-15-0279. Epub 2015 Aug 11. PMID:26263910

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Pediatr Blood Cancer. 2015 Nov;62(11):1897-905. doi: 10.1002/pbc.25611. Epub 2015 Jul 7. PMID:26154614

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Moradi Manesh D, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken LS, Hedrick A, Sutton R, Marshall GM, Wilson WR, Kurmasheva RT, Billups C, Houghton PJ, Smith MA, Carol H, Lock RB. Blood. 2015 Sep 3;126(10):1193-202. doi: 10.1182/blood-2014-12-618900. Epub 2015 Jun 26. PMID:26116659

The oncogenic role of the cochaperone Sgt1. Ogi H, Sakuraba Y, Kitagawa R, Xiao L, Shen C, Cynthia MA, Ohta S, Arnold MA, Ramirez N, Houghton PJ, Kitagawa K. Oncogenesis. 2015 May 18;4:e149. doi: 10.1038/oncsis.2015.12. PMID:25985210

Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Studebaker A, Bondra K, Seum S, Shen C, Phelps DA, Chronowski C, Leasure J, Smith PD, Kurmasheva RT, Mo X, Fouladi M, Houghton PJ. Pediatr Blood Cancer. 2015 Oct;62(10):1768-74. doi: 10.1002/pbc.25579. Epub 2015 May 15. PMID:25981859

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Phelps D, Bondra K, Seum S, Chronowski C, Leasure J, Kurmasheva RT, Middleton S, Wang D, Mo X, Houghton PJ. Pediatr Blood Cancer. 2015 Aug;62(8):1345-52. doi: 10.1002/pbc.25465. Epub 2015 Apr 1. PMID:25832557

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA. Pediatr Blood Cancer. 2015 Jul;62(7):1214-21. doi: 10.1002/pbc.25474. Epub 2015 Mar 23. PMID:25809532

Radiation therapy may increase metastatic potential in alveolar rhabdomyosarcoma. Woods GM, Bondra K, Chronowski C, Leasure J, Singh M, Hensley L, Cripe TP, Chakravarti A, Houghton PJ. Pediatr Blood Cancer. 2015 Sep;62(9):1550-4. doi: 10.1002/pbc.25516. Epub 2015 Mar 19. PMID:25790258

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Richmond J, Carol H, Evans K, High L, Mendomo A, Robbins A, Meyer C, Venn NC, Marschalek R, Henderson M, Sutton R, Kurmasheva RT, Kees UR, Houghton PJ, Smith MA, Lock RB. Clin Cancer Res. 2015 Mar 15;21(6):1395-405. doi: 10.1158/1078-0432.CCR-14-2300. Epub 2015 Jan 8. PMID:25573381

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. Suryani S, Bracken LS, Harvey RC, Sia KC, Carol H, Chen IM, Evans K, Dietrich PA, Roberts KG, Kurmasheva RT, Billups CA, Mullighan CG, Willman CL, Loh ML, Hunger SP, Houghton PJ, Smith MA, Lock RB. Mol Cancer Ther. 2015 Feb;14(2):364-74. doi: 10.1158/1535-7163.MCT-14-0647. Epub 2014 Dec 10. PMID:25504635

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1118-1119. PMID:25500058

A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, Thomas G, Mercer CA, Krueger DA, Houghton PJ, Doyle LA, Chen H, Weigel B, Blaney SM. Clin Cancer Res. 2015 Apr 1;21(7):1558-65. doi: 10.1158/1078-0432.CCR-14-0595. Epub 2014 Dec 2. PMID:25467181

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. doi: 10.1002/pbc.25329. Epub 2014 Nov 18. PMID:25407467

A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J.J Biol Chem. 2015 Feb 6;290(6):3418-29. doi: 10.1074/jbc.M114.616748. Epub 2014 Oct 13. PMID:25313399

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Pediatr Blood Cancer. 2015 Jan;62(1):91-8. doi: 10.1002/pbc.25201. Epub 2014 Sep 27. PMID:25263539

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA. Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. doi: 10.1002/pbc.25175. Epub 2014 Aug 17. PMID:25131802

Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Suryani S, Carol H, Chonghaile TN, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Manesh DM, Kurmasheva RT, Billups C, Kaplan W, Letai A, Bourquin JP, Houghton PJ, Smith MA, Lock RB. Clin Cancer Res. 2014 Sep 1;20(17):4520-31. doi: 10.1158/1078-0432.CCR-14-0259. Epub 2014 Jul 10. PMID:25013123

FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. Singh M, Leasure JM, Chronowski C, Geier B, Bondra K, Duan W, Hensley LA, Villalona-Calero M, Li N, Vergis AM, Kurmasheva RT, Shen C, Woods G, Sebastian N, Fabian D, Kaplon R, Hammond S, Palanichamy K, Chakravarti A, Houghton PJ. Clin Cancer Res. 2014 Jul 15;20(14):3884-95. doi: 10.1158/1078-0432.CCR-13-0556. Epub 2014 Apr 30.PMID: 24787670

p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage. Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam H. J Biol Chem. 2014 Feb 14;289(7):4083-94. doi: 10.1074/jbc.M113.530303. Epub 2013 Dec 23.PMID: 24366874

ΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam H. Cancer Res. 2014 Jan 1;74(1):320-9. doi: 10.1158/0008-5472.CAN-13-0894. Epub 2013 Oct 23.PMID: 24154873

miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ, London CA, Kraybill W, Perrotti D, Croce CM, Keller C, Guttridge DC. Sci Signal. 2013 Jul 30;6(286):ra63. doi: 10.1126/scisignal.2004177. Erratum in: Sci Signal. 2013 Sep 10;6(292):er6. Balkhi, Mumtaz Y [corrected to Balkhi, M Y]. PMID: 23901138

The mTOR pathway negatively controls ATM by up-regulating miRNAs. Shen C, Houghton PJ. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11869-74. doi: 10.1073/pnas.1220898110. Epub 2013 Jul 1.PMID: 23818585

Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJ. Cancer Res. 2013 Jun 1;73(11):3393-401. doi: 10.1158/0008-5472.CAN-12-4282. Epub 2013 Apr 30.PMID: 23633493

Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ. Clin Cancer Res. 2013 Jun 1;19(11):2984-94. doi: 10.1158/1078-0432.CCR-12-2008. Epub 2013 Apr 2.PMID: 23549869

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Bid HK, Zhan J, Phelps DA, Kurmasheva RT, Houghton PJ. Mol Cancer Ther. 2012 Mar;11(3):649-59. doi: 10.1158/1535-7163.MCT-11-0575. Epub 2011 Dec 21.PMID: 22188815

Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, van Laarhoven HW, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT. Clin Cancer Res. 2011 Dec 15;17(24):7693-703. doi: 10.1158/1078-0432.CCR-11-1488. Epub 2011 Oct 28.PMID: 22038993

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA.Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14. PMID: 21673091

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, Wozniak AW, Smith MA, Houghton PJ. Pediatr Blood Cancer. 2012 May;58(5):729-35. doi: 10.1002/pbc.23157. Epub 2011 May 31. PMID: 21630428

mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Cam H, Easton JB, High A, Houghton PJ.Mol Cell. 2010 Nov 24;40(4):509-20. doi: 10.1016/j.molcel.2010.10.030. PMID: 21095582

Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling. Thimmaiah KN, Easton JB, Houghton PJ.Cancer Res. 2010 Mar 1;70(5):2000-9. doi: 10.1158/0008-5472.CAN-09-3693. Epub 2010 Feb 23.PMID: 20179209

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ.Cancer Res. 2009 Oct 1;69(19):7662-71. doi: 10.1158/0008-5472.CAN-09-1693. Epub 2009 Sep 29.PMID: 19789339

 

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Jones L, Carol H, Evans K, Richmond J, Houghton PJ, Smith MA, Lock RB.Leukemia. 2016 Nov;30(11):2133-2141. doi: 10.1038/leu.2016.192. Epub 2016 Jul 15. Review.PMID:27416986

Identifying novel therapeutic agents using xenograft models of pediatric cancer. Kurmasheva RT, Houghton PJ.Cancer Chemother Pharmacol. 2016 Aug;78(2):221-32. doi: 10.1007/s00280-016-3042-6. Epub 2016 May 18. Review.PMID: 27193096

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ.Front Oncol. 2015 Aug 26;5:193. doi: 0.3389/fonc.2015.00193. eCollection 2015. Review.PMID:26380223

Targeting FANCD2 for therapy sensitization. Shen C, Houghton PJ.Oncotarget. 2014 Jun 15;5(11):3426-7. No abstract available. PMID:24913333

Rhabdomyosarcoma: current challenges and their implications for developing therapies. Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C. Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a025650. doi: 10.1101/cshperspect.a025650. Review.PMID: 25368019

Drug discovery in paediatric oncology: roadblocks to progress. Adamson PC, Houghton PJ, Perilongo G, Pritchard-Jones K.Nat Rev Clin Oncol. 2014 Dec;11(12):732-9. doi: 10.1038/nrclinonc.2014.149. Epub 2014 Sep 16. Review.PMID:25223555

Targeting FANCD2 for therapy sensitization. Shen C, Houghton PJ.Oncotarget. 2014 Jun 15;5(11):3426-7. No abstract available. PMID:24913333

Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences. Cam H, Houghton PJ. Target Oncol. 2011 Jun;6(2):95-102. doi: 10.1007/s11523-011-0173-x. Epub 2011 Apr 16. Review.PMID: 21499767

Targeting angiogenesis in childhood sarcomas. Bid HK, Houghton PJ. Sarcoma. 2011;2011:601514. doi: 10.1155/2011/601514. Epub 2010 Dec 9. PMID: 21197468 Everolimus. Houghton PJ. Clin Cancer Res. 2010 Mar 1;16(5):1368-72. doi: 10.1158/1078-0432.CCR-09-1314. Epub 2010 Feb 23. Review.PMID: 20179227